AZD2281
D0810C00012
Phase 2 small_molecule completed
Quick answer
AZD2281 for Ovarian Neoplasms is a Phase 2 program (small_molecule) at AstraZeneca with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca
- Indication
- Ovarian Neoplasms
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed